Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020

We conducted a second nationwide severe acute respiratory syndrome coronavirus 2 seroprevalence study in the Faroe Islands during November 2020. We found crude seroprevalence was 0.3% and prevalence was 0.4% after adjusting for test sensitivity and specificity. This low seroprevalence supports the p...

Full description

Bibliographic Details
Published in:Emerging Infectious Diseases
Main Authors: Maria Skaalum Petersen, Marin Strøm, Jógvan Páll Fjallsbak, Jóhanna Ljósá Hansen, Sólrun Larsen, Eina H. Eliasen, Malan Johansen, Anna Sofía Veyhe, Marnar Fríðheim Kristiansen, Pál Weihe
Format: Article in Journal/Newspaper
Language:English
Published: Centers for Disease Control and Prevention 2022
Subjects:
COVID-19
respiratory infections
severe acute respiratory syndrome coronavirus 2
SARS-CoV-2
SARS
coronavirus disease
Medicine
R
Infectious and parasitic diseases
RC109-216
Faroe Islands
Online Access:https://doi.org/10.3201/eid2801.210917
https://doaj.org/article/731c5a04305b4abd835f27d9c4a5b7cd
Description
Summary:We conducted a second nationwide severe acute respiratory syndrome coronavirus 2 seroprevalence study in the Faroe Islands during November 2020. We found crude seroprevalence was 0.3% and prevalence was 0.4% after adjusting for test sensitivity and specificity. This low seroprevalence supports the prevention strategies used in the Faroe Islands.

Similar Items